Pfizer Downplays Risk Of Tofacitinib Panel Review As It Pushes Focus On Innovation
This article was originally published in The Pink Sheet Daily
Capital allocation and business re-structuring dominated the conversation during Pfizer’s Q1 earnings call –its first full quarter without Lipitor exclusivity, even as the company waits for near-term regulatory decisions on key compounds.
You may also be interested in...
Oral Dosing May Not Be Enough To Win Speedy Adoption Of Pfizer’s RA Pill Xeljanz
Pfizer’s newly approved oral RA therapy Xeljanz has an oral advantage over established immune modulators, which all are delivered by needle, but safety questions may slow its adoption.
Pfizer Tofacitinib’s Fate May Rest On Radiographic Data
The marketability and even the approvability of the first-in-class JAK inhibitor for treatment of rheumatoid arthritis may hinge on whether it can be shown to offer patients a structural benefit. FDA briefing documents for the May 9 advisory committee review show issues with those findings.
Pfizer’s Pride-And-Joy Pain Drug Lyrica Slips In Two New Phase III Trials
One failed study tested Lyrica in a subset of difficult-to-treat patients in the approved indication of diabetic neuropathy, while another explored its use in neuropathic pain related to HIV.